Local view for "http://purl.org/linkedpolitics/eu/plenary/2004-01-13-Speech-2-090"
Predicate | Value (sorted: default) |
---|---|
rdf:type | |
dcterms:Date | |
dcterms:Is Part Of | |
dcterms:Language | |
lpv:document identification number |
"en.20040113.5.2-090"2
|
lpv:hasSubsequent | |
lpv:speaker | |
lpv:spokenAs | |
lpv:translated text |
".
I support this excellent report by Mr Pirker, which proposes a reshaping of the 1997 Joint Action, with a view to combating new synthetic drugs more rapidly and effectively.
We face the problem of a steady increase in the manufacture and trade in synthetic drugs and rigorous and effective forms of control must be put in place as a matter of urgency. This proposal seeks both to update this Joint Action and, at the same time, to ensure greater transparency and to extend the Joint Action’s scope as regards exchanging information, risk assessment and the control of new synthetic drugs. This has been an extremely effective instrument for ensuring a rapid exchange of information and the scope is now extended to all new synthetic drugs and narcotic drugs, including those likely to be defined as medicinal products.
We should also welcome the fact that the structures are to be simplified, as the rapporteur proposes, so as to ensure that information exchanges and risk assessments are carried out as simply and effectively as possible.
We hope that the Joint Action does not confine itself to operating simply as a rapid-response mechanism but also serves, in future, to provide long-term monitoring of synthetic substances through a constant exchange of information between the Member States, Europol and the EMCDDA."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples